UK Markets closed

Global Veterinary Oncology Market to Reach $400.2 Million by 2027

ReportLinker
·26-min read

Abstract: - Global Veterinary Oncology Market to Reach $400. 2 Million by 2027. - Amid the COVID-19 crisis, the global market for Veterinary Oncology estimated at US$215. 4 Million in the year 2020, is projected to reach a revised size of US$400.

New York, April 16, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Veterinary Oncology Industry" - https://www.reportlinker.com/p06033237/?utm_source=GNW
2 Million by 2027, growing at a CAGR of 9.3% over the analysis period 2020-2027. Radiology, one of the segments analyzed in the report, is projected to record a 8.6% CAGR and reach US$115.9 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Chemotherapy segment is readjusted to a revised 10% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $58.3 Million, While China is Forecast to Grow at 12.4% CAGR
- The Veterinary Oncology market in the U.S. is estimated at US$58.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$83.1 Million by the year 2027 trailing a CAGR of 12.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.3% and 7.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.
- Immunotherapy Segment to Record 9.7% CAGR
- In the global Immunotherapy segment, USA, Canada, Japan, China and Europe will drive the 9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$32.4 Million in the year 2020 will reach a projected size of US$59.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$57.1 Million by the year 2027, while Latin America will expand at a 11.1% CAGR through the analysis period.

- Select Competitors (Total 40 Featured) -

  • Accuray Incorporated

  • Boehringer Ingelheim International GmbH

  • Elanco

  • Karyopharm Therapeutics, Inc.

  • Morphogenesis, Inc.

  • Nippon Zenyaku Kogyo Co., Ltd.

  • One Health

  • PetCure Oncology

  • Regeneus Ltd.

  • Varian Medical System, Inc.




Read the full report: https://www.reportlinker.com/p06033237/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Veterinary
Oncology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Veterinary Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 3: World 15-Year Perspective for Veterinary Oncology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Radiology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 5: World Historic Review for Radiology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Radiology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Chemotherapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 8: World Historic Review for Chemotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Chemotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Immunotherapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 11: World Historic Review for Immunotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Immunotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Surgery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 14: World Historic Review for Surgery by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Surgery by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Other Therapies
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 17: World Historic Review for Other Therapies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 18: World 15-Year Perspective for Other Therapies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Canine by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 20: World Historic Review for Canine by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Canine by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Feline by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 23: World Historic Review for Feline by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Feline by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Lymphoma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 26: World Historic Review for Lymphoma by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Lymphoma by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Mast Cell Cancer
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 29: World Historic Review for Mast Cell Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 30: World 15-Year Perspective for Mast Cell Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Mammary &
Squamous Cell Cancer by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Mammary & Squamous Cell
Cancer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Mammary & Squamous Cell
Cancer by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 34: World Current & Future Analysis for Other Cancer
Types by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 35: World Historic Review for Other Cancer Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019 and % CAGR

Table 36: World 15-Year Perspective for Other Cancer Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 37: USA Current & Future Analysis for Veterinary Oncology
by Therapy - Radiology, Chemotherapy, Immunotherapy, Surgery
and Other Therapies - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Veterinary Oncology by
Therapy - Radiology, Chemotherapy, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Radiology,
Chemotherapy, Immunotherapy, Surgery and Other Therapies for
the Years 2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Veterinary Oncology
by Animal Type - Canine and Feline - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Veterinary Oncology by Animal
Type - Canine and Feline Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2020 & 2027

Table 43: USA Current & Future Analysis for Veterinary Oncology
by Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 44: USA Historic Review for Veterinary Oncology by Cancer
Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell
Cancer and Other Cancer Types Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2020 & 2027

CANADA
Table 46: Canada Current & Future Analysis for Veterinary
Oncology by Therapy - Radiology, Chemotherapy, Immunotherapy,
Surgery and Other Therapies - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Veterinary Oncology by
Therapy - Radiology, Chemotherapy, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Radiology,
Chemotherapy, Immunotherapy, Surgery and Other Therapies for
the Years 2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Veterinary
Oncology by Animal Type - Canine and Feline - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 50: Canada Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2020 & 2027

Table 52: Canada Current & Future Analysis for Veterinary
Oncology by Cancer Type - Lymphoma, Mast Cell Cancer, Mammary &
Squamous Cell Cancer and Other Cancer Types - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 53: Canada Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 54: Canada 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2020 & 2027

JAPAN
Table 55: Japan Current & Future Analysis for Veterinary
Oncology by Therapy - Radiology, Chemotherapy, Immunotherapy,
Surgery and Other Therapies - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Veterinary Oncology by
Therapy - Radiology, Chemotherapy, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Radiology,
Chemotherapy, Immunotherapy, Surgery and Other Therapies for
the Years 2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Veterinary
Oncology by Animal Type - Canine and Feline - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 59: Japan Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2020 & 2027

Table 61: Japan Current & Future Analysis for Veterinary
Oncology by Cancer Type - Lymphoma, Mast Cell Cancer, Mammary &
Squamous Cell Cancer and Other Cancer Types - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 62: Japan Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 63: Japan 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2020 & 2027

CHINA
Table 64: China Current & Future Analysis for Veterinary
Oncology by Therapy - Radiology, Chemotherapy, Immunotherapy,
Surgery and Other Therapies - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Veterinary Oncology by
Therapy - Radiology, Chemotherapy, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ for Years 2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Radiology,
Chemotherapy, Immunotherapy, Surgery and Other Therapies for
the Years 2012, 2020 & 2027

Table 67: China Current & Future Analysis for Veterinary
Oncology by Animal Type - Canine and Feline - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 68: China Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2020 & 2027

Table 70: China Current & Future Analysis for Veterinary
Oncology by Cancer Type - Lymphoma, Mast Cell Cancer, Mammary &
Squamous Cell Cancer and Other Cancer Types - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 71: China Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 72: China 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2020 & 2027

EUROPE
Table 73: Europe Current & Future Analysis for Veterinary
Oncology by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Veterinary Oncology by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Veterinary Oncology by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Veterinary
Oncology by Therapy - Radiology, Chemotherapy, Immunotherapy,
Surgery and Other Therapies - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Veterinary Oncology by
Therapy - Radiology, Chemotherapy, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Radiology,
Chemotherapy, Immunotherapy, Surgery and Other Therapies for
the Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Veterinary
Oncology by Animal Type - Canine and Feline - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 80: Europe Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2020 & 2027

Table 82: Europe Current & Future Analysis for Veterinary
Oncology by Cancer Type - Lymphoma, Mast Cell Cancer, Mammary &
Squamous Cell Cancer and Other Cancer Types - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 83: Europe Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 84: Europe 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2020 & 2027

FRANCE
Table 85: France Current & Future Analysis for Veterinary
Oncology by Therapy - Radiology, Chemotherapy, Immunotherapy,
Surgery and Other Therapies - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Veterinary Oncology by
Therapy - Radiology, Chemotherapy, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ for Years 2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Radiology,
Chemotherapy, Immunotherapy, Surgery and Other Therapies for
the Years 2012, 2020 & 2027

Table 88: France Current & Future Analysis for Veterinary
Oncology by Animal Type - Canine and Feline - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 89: France Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2020 & 2027

Table 91: France Current & Future Analysis for Veterinary
Oncology by Cancer Type - Lymphoma, Mast Cell Cancer, Mammary &
Squamous Cell Cancer and Other Cancer Types - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 92: France Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 93: France 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2020 & 2027

GERMANY
Table 94: Germany Current & Future Analysis for Veterinary
Oncology by Therapy - Radiology, Chemotherapy, Immunotherapy,
Surgery and Other Therapies - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 95: Germany Historic Review for Veterinary Oncology by
Therapy - Radiology, Chemotherapy, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ for Years 2012 through 2019 and % CAGR

Table 96: Germany 15-Year Perspective for Veterinary Oncology
by Therapy - Percentage Breakdown of Value Sales for Radiology,
Chemotherapy, Immunotherapy, Surgery and Other Therapies for
the Years 2012, 2020 & 2027

Table 97: Germany Current & Future Analysis for Veterinary
Oncology by Animal Type - Canine and Feline - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 98: Germany Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 99: Germany 15-Year Perspective for Veterinary Oncology
by Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2020 & 2027

Table 100: Germany Current & Future Analysis for Veterinary
Oncology by Cancer Type - Lymphoma, Mast Cell Cancer, Mammary &
Squamous Cell Cancer and Other Cancer Types - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 101: Germany Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 102: Germany 15-Year Perspective for Veterinary Oncology
by Cancer Type - Percentage Breakdown of Value Sales for
Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer and
Other Cancer Types for the Years 2012, 2020 & 2027

ITALY
Table 103: Italy Current & Future Analysis for Veterinary
Oncology by Therapy - Radiology, Chemotherapy, Immunotherapy,
Surgery and Other Therapies - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 104: Italy Historic Review for Veterinary Oncology by
Therapy - Radiology, Chemotherapy, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ for Years 2012 through 2019 and % CAGR

Table 105: Italy 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Radiology,
Chemotherapy, Immunotherapy, Surgery and Other Therapies for
the Years 2012, 2020 & 2027

Table 106: Italy Current & Future Analysis for Veterinary
Oncology by Animal Type - Canine and Feline - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 107: Italy Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 108: Italy 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2020 & 2027

Table 109: Italy Current & Future Analysis for Veterinary
Oncology by Cancer Type - Lymphoma, Mast Cell Cancer, Mammary &
Squamous Cell Cancer and Other Cancer Types - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 110: Italy Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 111: Italy 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 112: UK Current & Future Analysis for Veterinary Oncology
by Therapy - Radiology, Chemotherapy, Immunotherapy, Surgery
and Other Therapies - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 113: UK Historic Review for Veterinary Oncology by
Therapy - Radiology, Chemotherapy, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ for Years 2012 through 2019 and % CAGR

Table 114: UK 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Radiology,
Chemotherapy, Immunotherapy, Surgery and Other Therapies for
the Years 2012, 2020 & 2027

Table 115: UK Current & Future Analysis for Veterinary Oncology
by Animal Type - Canine and Feline - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 116: UK Historic Review for Veterinary Oncology by Animal
Type - Canine and Feline Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 117: UK 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2020 & 2027

Table 118: UK Current & Future Analysis for Veterinary Oncology
by Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 119: UK Historic Review for Veterinary Oncology by Cancer
Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell
Cancer and Other Cancer Types Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 120: UK 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2020 & 2027

SPAIN
Table 121: Spain Current & Future Analysis for Veterinary
Oncology by Therapy - Radiology, Chemotherapy, Immunotherapy,
Surgery and Other Therapies - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 122: Spain Historic Review for Veterinary Oncology by
Therapy - Radiology, Chemotherapy, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ for Years 2012 through 2019 and % CAGR

Table 123: Spain 15-Year Perspective for Veterinary Oncology by
Therapy - Percentage Breakdown of Value Sales for Radiology,
Chemotherapy, Immunotherapy, Surgery and Other Therapies for
the Years 2012, 2020 & 2027

Table 124: Spain Current & Future Analysis for Veterinary
Oncology by Animal Type - Canine and Feline - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 125: Spain Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 126: Spain 15-Year Perspective for Veterinary Oncology by
Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2020 & 2027

Table 127: Spain Current & Future Analysis for Veterinary
Oncology by Cancer Type - Lymphoma, Mast Cell Cancer, Mammary &
Squamous Cell Cancer and Other Cancer Types - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 128: Spain Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 129: Spain 15-Year Perspective for Veterinary Oncology by
Cancer Type - Percentage Breakdown of Value Sales for Lymphoma,
Mast Cell Cancer, Mammary & Squamous Cell Cancer and Other
Cancer Types for the Years 2012, 2020 & 2027

RUSSIA
Table 130: Russia Current & Future Analysis for Veterinary
Oncology by Therapy - Radiology, Chemotherapy, Immunotherapy,
Surgery and Other Therapies - Independent Analysis of Annual
Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 131: Russia Historic Review for Veterinary Oncology by
Therapy - Radiology, Chemotherapy, Immunotherapy, Surgery and
Other Therapies Markets - Independent Analysis of Annual Sales
in US$ for Years 2012 through 2019 and % CAGR

Table 132: Russia 15-Year Perspective for Veterinary Oncology
by Therapy - Percentage Breakdown of Value Sales for Radiology,
Chemotherapy, Immunotherapy, Surgery and Other Therapies for
the Years 2012, 2020 & 2027

Table 133: Russia Current & Future Analysis for Veterinary
Oncology by Animal Type - Canine and Feline - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 134: Russia Historic Review for Veterinary Oncology by
Animal Type - Canine and Feline Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 135: Russia 15-Year Perspective for Veterinary Oncology
by Animal Type - Percentage Breakdown of Value Sales for Canine
and Feline for the Years 2012, 2020 & 2027

Table 136: Russia Current & Future Analysis for Veterinary
Oncology by Cancer Type - Lymphoma, Mast Cell Cancer, Mammary &
Squamous Cell Cancer and Other Cancer Types - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 137: Russia Historic Review for Veterinary Oncology by
Cancer Type - Lymphoma, Mast Cell Cancer, Mammary & Squamous
Cell Cancer and Other Cancer Types Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 138: Russia 15-Year Perspective for Veterinary Oncology
by Cancer Type - Percentage Breakdown of Value Sales for

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06033237/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001